免疫球蛋白替代治疗对成人鼻窦炎伴原发性体液免疫缺陷的疗效
回顾性队列研究纳入58例接受免疫球蛋白替代治疗的成人原发性体液免疫缺陷伴复发性鼻窦炎患者,比较治疗前后鼻窦感染次数、Lund-Mackay评分及FESS需求。
要点
- IG替代治疗可显著降低PID伴鼻窦炎患者的LM评分和FESS需求。
- 治疗后58.6%患者无鼻窦感染复发,其余仅每年1-5次感染。
- 证据等级为4级,提示需谨慎解读,尚需更高质量研究验证。
核心结论
- IG替代治疗是PID患者复发性鼻窦炎的有前景的治疗选择。
研究设计与样本
- 回顾性队列研究,纳入58例18岁及以上诊断为PID并伴有复发性急性鼻窦炎或慢性鼻窦炎的成人患者,均接受IG替代治疗。
关键数值与推荐
- 患者平均年龄52岁(18-79岁),约74%为女性;51.7%为CVID,31.1%为低丙种球蛋白血症,17.2%为SAD;79%合并过敏性鼻炎,74%合并哮喘。
临床怎么用
- 对于PID伴复发性鼻窦炎的成人患者,IG替代治疗可减少鼻窦感染次数、降低LM评分并减少FESS需求。
局限性
- 回顾性研究设计,证据等级为4级;样本量有限,可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the outcome of immunoglobulin (IG) replacement therapy in adults with rhinosinusitis and primary humoral immunodeficiency disorders (PID). STUDY DESIGN: Retrospective cohort study. METHODS: Retrospective chart review of adult (18 years and older) patients who were diagnosed with PID and had the diagnosis of recurrent acute rhinosinusitis (RARS) and chronic rhinosinusitis (CRS) and who are on IG replacement therapy. Demographic data, associated conditions, and duration of treatment were reviewed. Number of yearly sinus infections, sinus CT Lund-Mackay (LM) score, and need for functional endoscopic sinus surgery (FESS) were reviewed before and after starting IG therapy. RESULTS: Fifty-eight patients were included. Average age was 52 years (18-79 years). About 74% were female. Thirty patients (51.7%) had common variable immunodeficiency (CVID), 18 (31.1%) had hypogammaglobulinemia, and 10 (17.2%) had specific antibody deficiency (SAD). About 79% of patients had allergic rhinitis and 74% had asthma. Pretreatment LM score was 7.6 (±2.2, range of 0-24) compared to posttreatment score of 3.5 (±1.3, range of 0-16) (P = .01). Eleven patients (19%) had FESS pretreatment compared to only two patients (3.4%) requiring ESS after starting treatment on IG therapy (P = .004). Prior to starting IG therapy, five patients (8.6%) had more than 10 sinus infections per year, 33 patients (56.9%) had 5 to 10 infections, and 20 patients (34.5%) had 1 to 5 infections per year. After starting on IG, 34 patients (58.6%) had no infections reported anymore (P < .001), and 24 patients (41.4%) had only 1 to 5 infections reported per year CONCLUSION: IG therapy is a promising treatment option for recurrent rhinosinusitis in patients with PID. LEVEL OF EVIDENCE: 4 Laryngoscope, 132:732-736, 2022.
引用
- Makary CA, Behnke J, Peppers B, et al. Outcome of Immunoglobulin Replacement Therapy in Adults With Rhinosinusitis. Laryngoscope. 2021. PMID: 34146351. doi:10.1002/lary.29694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。